# Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

- Source: PR Newswire M&A
- Published: 2026-11-06T04:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-nmpa-acceptance-of-new-drug-application-for-zemprocitinib-in-the-treatment-of-rheumatoid-arthritis-302931678.html
- Canonical: https://groundlevelnews.com/story/lynk-pharmaceuticals-announces-nmpa-acceptance-of-new-drug-application-786b1e/

SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._